Sanara MedTech (NASDAQ:SMTI) Shares Down 0.2%

Sanara MedTech Inc. (NASDAQ:SMTI - Get Free Report)'s share price was down 0.2% during mid-day trading on Wednesday . The stock traded as low as $31.53 and last traded at $31.60. Approximately 9,594 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 13,296 shares. The stock had previously closed at $31.65.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald lowered their target price on shares of Sanara MedTech from $49.00 to $44.00 and set an "overweight" rating for the company in a report on Wednesday, March 27th.

Sanara MedTech Stock Down 0.2 %

The business's fifty day moving average is $36.55 and its two-hundred day moving average is $34.73. The company has a market cap of $272.39 million, a P/E ratio of -60.77 and a beta of 1.57. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last announced its quarterly earnings data on Monday, March 25th. The company reported ($0.03) earnings per share for the quarter. Sanara MedTech had a negative net margin of 6.62% and a negative return on equity of 11.12%. The company had revenue of $17.69 million for the quarter. Equities analysts predict that Sanara MedTech Inc. will post -0.22 EPS for the current year.

Institutional Investors Weigh In On Sanara MedTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SMTI. Tower Research Capital LLC TRC increased its position in Sanara MedTech by 363.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 797 shares of the company's stock valued at $25,000 after purchasing an additional 625 shares during the period. UBS Group AG increased its position in Sanara MedTech by 138.8% during the 1st quarter. UBS Group AG now owns 609 shares of the company's stock valued at $25,000 after purchasing an additional 354 shares during the period. Barclays PLC purchased a new position in Sanara MedTech during the 2nd quarter valued at about $30,000. Gladius Capital Management LP purchased a new position in Sanara MedTech during the 4th quarter valued at about $45,000. Finally, California State Teachers Retirement System purchased a new position in Sanara MedTech during the 2nd quarter valued at about $51,000. Institutional investors own 8.10% of the company's stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.